Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bicara Therapeutics Inc (BCAX)

Bicara Therapeutics Inc (BCAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 917,599
  • Shares Outstanding, K 54,782
  • Annual Sales, $ 0 K
  • Annual Income, $ -68,000 K
  • EBIT $ -141 M
  • EBITDA $ -141 M
  • 60-Month Beta -0.79
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.27

Options Overview Details

View History
  • Implied Volatility 189.42% (-56.34%)
  • Historical Volatility 50.91%
  • IV Percentile 74%
  • IV Rank 54.56%
  • IV High 321.03% on 09/26/25
  • IV Low 31.38% on 09/08/25
  • Expected Move (DTE 31) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6
  • Volume Avg (30-Day) 144
  • Put/Call OI Ratio 3.58
  • Today's Open Interest 2,181
  • Open Int (30-Day) 2,203
  • Expected Range 16.67 to 16.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.72
  • Number of Estimates 6
  • High Estimate -0.68
  • Low Estimate -0.76
  • Prior Year -0.39
  • Growth Rate Est. (year over year) -84.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.64 +8.41%
on 01/05/26
18.49 -8.30%
on 12/23/25
-0.65 (-3.66%)
since 12/19/25
3-Month
13.70 +23.76%
on 11/11/25
19.68 -13.85%
on 12/11/25
+0.69 (+4.27%)
since 10/20/25
52-Week
7.80 +117.37%
on 05/23/25
19.71 -13.98%
on 10/13/25
+4.85 (+40.01%)
since 01/17/25

Most Recent Stories

More News
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook

Selected 1500 mg of ficerafusp alfa as the optimal dose for the treatment of 1L HPV-negative R/M HNSCC in Phase 3 FORTIFI-HN01 pivotal study Expects to achieve substantial enrollment in FORTIFI-HN01...

BCAX : 17.02 (+1.61%)
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 17.02 (+1.61%)
Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study interim...

BCAX : 17.02 (+1.61%)
Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates overall response rate and safety profile consistent with the 1500mg QW dose Data inform and advance progress toward dose selection...

BCAX : 17.02 (+1.61%)
Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Granted FDA Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC Data from a Phase 1b expansion cohort evaluating 750mg of ficerafusp...

BCAX : 17.02 (+1.61%)
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology

EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOBT),(NYSE:NVS),(NASDAQ:BCAX),(NYSE:PFE) EQNX::TICKER_END

BCAX : 17.02 (+1.61%)
OTLC : 0.0777 (-3.96%)
IOBT : 0.5020 (-0.02%)
NVS : 144.57 (+0.16%)
PFE : 25.49 (-0.62%)
Analysts Offer Insights on Healthcare Companies: Bicara Therapeutics Inc. (BCAX) and HUTCHMED (HCM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bicara Therapeutics Inc. (BCAX – Research Report) and HUTCHMED (HCM – Research Report) with bullish...

HCM : 15.70 (-2.18%)
BCAX : 17.02 (+1.61%)
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC 

BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 17.02 (+1.61%)
TD Cowen Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)

In a report released on September 30, Tyler Van Buren from TD Cowen maintained a Buy rating on Bicara Therapeutics Inc.. The company’s shares closed yesterday at $16.61.Elevate Your Investing Strategy:...

BCAX : 17.02 (+1.61%)
Bicara Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 17.02 (+1.61%)

Business Summary

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. The company's lead asset includes ficerafusp alfa. Bicara Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 17.72
2nd Resistance Point 17.44
1st Resistance Point 17.09
Last Price 17.02
1st Support Level 16.47
2nd Support Level 16.19
3rd Support Level 15.85

See More

52-Week High 19.71
Last Price 17.02
Fibonacci 61.8% 15.16
Fibonacci 50% 13.75
Fibonacci 38.2% 12.35
52-Week Low 7.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar